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pretest. RESULTS: With the author’s approval, the ques-
tionnaire was translated from English to French by two
independent translators. The two versions were compared
and a few non signiﬁcant differences were noted. The
translations were discussed and reviewed, item-by-item,
until a consensus was achieved: version 3. The version 3
was critically reviewed by a bilingual expert version 4. A
bilingual translator back-translated version 4 in version
4b which after discussion with the main author has been
accepted as expressing the questions in the same way as
the original version. CONCLUSION: To make sure that
the translation is consistent with our objective, the pretest
analysis is ongoing among 20 patients. For a large-scale
validation, this questionnaire will be remitted during a
clinical trial on a new therapeutic strategy in more than
80 patients.
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Skin diseases have a strong impact on the physical and
mental well-being of the patient. This is conﬁrmed by the
large number of quality of life studies that exist. Psoria-
sis and atopic dermatitis are the two most frequents
chronic dermatosis, therefore we estimated relevant to
cross-compare the patients’ quality of life. OBJECTIVES:
The Avène Dermatological Hydrotherapy Centre, which
welcomes over 2500 patients a year, offers real unity 
conditions of time and location in order to realise a 
cross-analysis. METHOD: A generic scale (SF-12) and a
speciﬁc scale (DLQI—Dermatology Life Quality Index)
are completed by each patient at their arrival at the Avène
Dermatological Hydrotherapy Centre. The completed
questionnaires were returned by post. RESULTS: In the
analysed population, the mean age is respectively 40.5
years old versus 55.5y.o. for patients suffering atopic der-
matitis (n = 141) versus psoriasis (n = 54) (p < 0.00001).
The DLQI score at inclusion is 37.84 for atopic dermati-
tis patients, 32.81 for psoriasis patients. Concerning the
SF-12, the results consisted of 2 scores: mental (MCS-12)
and physical (PCS-12). At inclusion the atopic dermatitis
patients scores were: PCS-12 = 47.5 & MCS-12 = 33.8,
the psoriasis patients scores were: PCS-12 = 46.3 & MCS-
12 = 39.0. If those two scales’ results show evidence of
an impairment in patients’ quality of life, no difference is
demonstrated between the two groups. CONCLUSION:
Those ﬁrst results demonstrated an equal impairment in
quality of life for patients suffering either from atopic 
dermatitis than psoriasis.
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Skin diseases have a strong impact on the physical and
mental well-being of the patient. This is conﬁrmed by the
large number of quality of life studies that exist. It is clear
that dermatological diseases affect not only the life of the
children but also that of his/her family. OBJECTIVES:
The Avène Dermatological Hydrotherapy Center, wel-
comes over 2500 patients a year suffering from skin 
diseases. The objective of the study is to demonstrate the
relevance of the long term effects of hydrotherapy treat-
ments on patients quality of life. METHOD: A generic
scale (SF-12) and a speciﬁc scale (DLQI—Dermatology
Life Quality Index) are completed by each patient at their
arrival at the Avène Dermatological Hydrotherapy Center
(inclusion), at the end of hydrotherapy cares (3 weeks)
and at 3 and 6 months. The completed questionnaires
were returned by post. RESULTS: In this ﬁrst analysis,
the ﬁrst 30 patients suffering from the three following
conditions: psoriasis, atopic dermatitis were taken into
account and analysed at inclusion and at the 6 months
after the hydrotherapy cares. The DLQI score at inclu-
sion is 32.1. At 6 months the DLQI score is 24.2. These
ﬁrst results show evidence of an improvement of patients’
quality of life 6 months after hydrotherapy treatments 
(p < 0.02). CONCLUSION: These ﬁrst results show evi-
dence of an improvement of patients’ quality of life 6
months after hydrotherapy treatments.
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OBJECTIVE: To evaluate the effect of psoriasis on
quality of life of patients in Spain. MEHOD: Four thou-
sand ﬁve hundred anonymous questionnaires (comprised
of two scales: the Psoriasis Disability Index (PDI) plus 10
questions concerning treatment and evolution of psoria-
sis) were sent, via a Psoriasis Patient Support Group
(AccionPsoriasis). RESULTS: Nineteen hundred ques-
tionnaires were returned (June 2002): response rate 42%.
An analysis of the ﬁrst 810 questionnaires was realised.
The sex ratio Men (M)/Women(W) was 49/51. Mean age:
42 years. Mean age of diagnosis: 21.8 years. The average
to the total score was 8.47 (s.d. 7.2 rank 0 to 39) i.e.
18.82 (s.d: 17.2) when reported to a scale of 0 to 100.
Signiﬁcative difference was observed between M and W
for the global handicap score 20.73 vs 16.95 p < 0.002.
Two groups was identiﬁed: pousée de psoriasis (84%),
